Chromaderm
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, Chromaderm sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).
Chromaderm: 9 sponsored US clinical trials, none currently recruiting.
Chromaderm sponsors 9 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 9 completed. 5 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Diabetic Neuropathy, with 1 trials.
Top-decile sponsor footprint
Chromaderm ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Indexed trials (enrollment closed)
9 total, page 1 of 1
Treatment for Completers of the Study B7A-MC-MBCM
NCT00266695
Effect of Ruboxistaurin on Clinically Significant Macular Edema
NCT00133952
The Effect of Ruboxistaurin on Small Fiber Function
NCT00190970
Reduction in the Occurrence of Center-Involved Diabetic Macular Edema
NCT00090519
Effect of LY333531 on Vascular and Neural Functions
NCT00482976
Isoprostane/FMD Study The Effect of Protein Kinase C (PKC) β Specific Inhibitor LY333531 on Oxidant Stress in Patients With Type 2 Diabetes Mellitus
NCT00552227
The Effect of LY333531 on Protein in the Urine in Patients With Type 2 Diabetes
NCT00044148
Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes
NCT00044408
Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study
NCT00604383
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 3 |
| Phase 3 | 5 |
Therapeutic Areas
How the Chromaderm archive is shaped
9 indexed studies, none listed as recruiting (0% open); 9 completed (100%).
Phase mix: 5 late (III/IV) vs 4 early (I/II) (balanced across stages).
Top condition: Diabetic Neuropathy (1 trial), 2 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Chromaderm: archived-pipeline peers nationwide
Peers matched on 9 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Chromaderm sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 9 archived trials
- 4D Molecular Therapeutics · 9 trials · 44% recruiting
- 9 Meters Biopharma · 9 trials · 0% recruiting
- Aadi Bioscience · 9 trials · 33% recruiting
- Ablynx, a Sanofi company · 9 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Chromaderm page
9 registered trials is a research-attention snapshot, not an endorsement of Chromaderm or any single study.
- None of Chromaderm's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Diabetic Neuropathy is the condition Chromaderm studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Diabetic Neuropathy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Chromaderm pipeline card: 9 registered trials from official public datasets.Report a data error.